Select Language

HLA-A*0301 & B2M & KRASG12V (VVGAVGVGK)

HLA-A*0301 & B2M & KRASG12V (VVGAVGVGK) Product List

Product Category
Protein (2)
Product Status
Launched (2)
Species
Human (2)
Tag
His Tag & Avi Tag (1)His Tag (1)
Conjugate
Biotin-labeled (1)PE Labeled (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
HLV-H82E9	Human	HEK293	Biotinylated Human HLA-A*03:01&B2M&KRASG12V (VVGAVGVGK) Complex Protein (Monomer, MALS verified)
HLV-HP2H8	Human	HEK293	PE-Labeled Human HLA-A*03:01&B2M&KRASG12V (VVGAVGVGK) Tetramer Protein

Total: 2

HLA-A*0301 & B2M & KRASG12V (VVGAVGVGK) Background

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Biotinylated Human HLA-A*0301 KRASG12V (VVGAVGVGK) complex protein is a complex of HLA-A*0301 of the MHC Class I, B2M, and VVGAVGVGK peptide of the KRASG12V.

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
DNDI-6148	DNDI-6148	Phase 1 Clinical	Drugs For Neglected Diseases Initiative	Infections; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral	Details
AN-3661	AN-6426; AN-3661	Phase 1 Clinical	Anacor Pharmaceuticals Inc	Malaria	Details